Gilead Sciences Inc.
Company Snapshot
Founded: 1987
Entity Type: Public
Employees: 17,000
Region: U.S.
Revenue: $29,443.0 Millions
Revenue Year: 2025
Segment: Cell Therapy
Headquarter: California, U.S.
Key Geographics: U.S., Europe
Corporate Address: 333 Lakeside Drive, Foster City, California 94404, U.S. Tel. +1-650-574-3000 www.gilead.com
Company Overview
Gilead Sciences Inc. is a biopharmaceutical company headquartered in the U.S. that develops, manufactures, and commercializes prescription medicines. Its operations are centered on research, clinical development, regulatory approval, manufacturing oversight, and global distribution of branded drugs. Its primary therapeutic focus areas include HIV, liver diseases, oncology, and inflammatory conditions. It manages a broad clinical development program, running late-stage and early-stage trials across multiple regions, and maintains internal capabilities for drug discovery and formulation.
Financial Highlights (FY 2025)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Gilead Sciences Inc. In News
Company's Business Segments
- HIV : Biktarvy, Genvoya, Descovy, Odefsey, Complera /Eviplera, Truvada, Stribild, Sunlenca, Veklury, Epclusa, Vemlidy, Harvon, Viread
- Oncology : Yescarta, Trodelvy, Tecartus
- Liver Disease : Ledipasvir/ Sofosbuvi, Sofosbuvir/Velpatasvir, Other HCV, Vemlidy, Viread, Other HBV/HDV
- Veklury : Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor
- Other : AmBisome, Letairis, Royalty, contract and other revenues
Applications/End User Industries
- Theapeutic Area
- Medicines
- Pipeline
- Research
- Clinical Trials
- Pharmaceutical Companies